Destacados de la literatura
Efecto del natalizumab sobre la actividad de la enfermedad clínica y radiológica en la esclerosis múltiple: un análisis retrospectivo del estudio Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM)
P. Zuberbuhler
Servicio de Neurología, Hospital General de Agudos Dr. T. Álvarez, Buenos Aires, Argentina
Leído
700
Vecesse ha leído el artículo
184
Total PDF
516
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 9 | 1 | 10 |
| 2025 11 | 18 | 15 | 33 |
| 2025 10 | 16 | 9 | 25 |
| 2025 9 | 24 | 11 | 35 |
| 2025 8 | 21 | 11 | 32 |
| 2025 7 | 40 | 9 | 49 |
| 2025 6 | 26 | 5 | 31 |
| 2025 5 | 20 | 11 | 31 |
| 2025 4 | 15 | 4 | 19 |
| 2025 3 | 18 | 2 | 20 |
| 2025 2 | 16 | 2 | 18 |
| 2025 1 | 12 | 4 | 16 |
| 2024 12 | 21 | 2 | 23 |
| 2024 11 | 14 | 5 | 19 |
| 2024 10 | 8 | 3 | 11 |
| 2024 9 | 13 | 6 | 19 |
| 2024 8 | 9 | 2 | 11 |
| 2024 7 | 12 | 6 | 18 |
| 2024 6 | 11 | 2 | 13 |
| 2024 5 | 12 | 2 | 14 |
| 2024 4 | 11 | 2 | 13 |
| 2024 3 | 16 | 9 | 25 |
| 2024 2 | 10 | 7 | 17 |
| 2024 1 | 6 | 1 | 7 |
| 2023 12 | 8 | 7 | 15 |
| 2023 11 | 5 | 8 | 13 |
| 2023 10 | 16 | 10 | 26 |
| 2023 9 | 25 | 7 | 32 |
| 2023 8 | 11 | 7 | 18 |
| 2023 7 | 8 | 5 | 13 |
| 2023 6 | 6 | 3 | 9 |
| 2023 5 | 38 | 3 | 41 |
| 2023 4 | 21 | 3 | 24 |
Mostrar todo
